Medicine and device safety updates | 16 November 2026
- 17-11-2026
- Posted by: Eldaniz Hasanov
- Category: Regulatory Updates
Medicine and device safety updates | 16 November 2026
Nine official medicine and device safety actions from Australia, Singapore, France and New Zealand, including a retrospectively verified New Zealand action dated 11 November.
Farganesse: promethazine injection recall
HSA · HSA public recall; Class 1. Notice / document or action commencement: 2026-11-16 / 2026-11-12.
HSA reports particles in Farganesse Injection 50 mg/2 ml ampoules. Its table identifies batches 0015318, 0015319, 0015320 and 0015321. The retail recall is Class 1, the category for potentially serious health consequences. Hospitals, clinics and pharmacies should stop supplying the affected batches and return stock as directed. The recall began on 12 November; HSA posted the notice on 16 November.
Andrographis Antitox Formula: consumer recall
TGA · RC-2026-RN-00931-1. Notice / document or action commencement: first observed 2026-11-16 / 2026-11-12.
TGA lists a Class I consumer recall of Chuan Xin Lian Jie Du Fang (Andrographis Antitox Formula), batch CM052024105, expiring 3 June 2028. Continuing anaphylaxis reports with Andrographis paniculata medicines underpin the action despite existing warnings. Suppliers should quarantine and return affected stock; consumers should stop using it and return it to the seller. This product action follows an already recognised safety concern.
Ki Cold & Flu: all unexpired batches recalled
TGA · RC-2026-RN-00937-1. Notice / document or action commencement: first observed 2026-11-16 / 2026-11-12.
TGA records a Class I consumer recall covering all unexpired batches of Ki Cold & Flu Attack and Ki Cold & Flu Day/Night Formula, codes MPZKICF30 and MPKICFDN30. The action concerns anaphylaxis associated with Andrographis paniculata. Supply-chain stock should be quarantined and returned, and consumers should stop use and seek a refund through the stated channels. The action commenced on 12 November and concerns specific products within the established risk.
Philips Incisive CT: software correction
TGA · RC-2026-RN-00927-1. Notice / document or action commencement: first observed 2026-11-16 / 2026-11-12.
TGA describes two Incisive CT software issues: patient-orientation information may disappear with Precise Position, and a particular mouse-button sequence can disrupt scan triggering in manual ROI bolus tracking. The hospital-level action is a Class II correction for V4.5/V5.0. Pending the Philips fix, users should verify patient orientation before the surview and follow the notice’s ROI workflow precautions, including preference for automatic ROI.
EdgeLab: antibiotic-susceptibility result mix-up
ANSM · R2634047; FSN-0004(AA). Notice / document or action commencement: 2026-11-16 / 2026-11-02.
In Log identifies a bacteriology ranking-mode scenario in EdgeLab 7.3.0 and earlier that can assign one organism’s susceptibility results to another. Incorrect results could lead to unsuitable medication or treatment. Support is deploying a workaround; the letter schedules the permanent correction for version 7.4.0 in the second half of 2027. Users should follow the supplier’s instructions and acknowledge the notice.
Official communication · Primary safety letter
Genexus Dx: cybersecurity software update
ANSM · R2633840; PR 961455. Notice / document or action commencement: 2026-11-16 / November 2026; exact day not specified.
The Ion Torrent Genexus Dx notice covers version 6.8.4.0 and earlier. Exploitation could make results unavailable, incomplete or altered, including false positives or negatives. The letter reports no confirmed exploitation, associated adverse events or patient harm. Version 6.8.4.1 addresses the vulnerabilities. Interim instructions cover authorised access, network protection, monitoring unusual connections and backing up data before the update.
Official communication · Primary safety letter
FlexLab X: electrical connection inspection
ANSM · R2631147; INPS 27-01.A.OUS; FSCA-FXX-202610-01. Notice / document or action commencement: 2026-11-16 / 2026-11-05 covering letter; Inpeco 2026-10-13.
Inpeco’s notice, distributed by Siemens, concerns FlexLab X power components MEE0074, MEE0075 and MEE0082. Potential consequences include delayed results, smoke and electric shock under specified failure sequences; the manufacturer rates the described risks as low overall. Users must leave access and repairs to authorised service staff. Electrical abnormalities require taking the system out of service and arranging the prescribed inspection and any replacement.
Official communication · Primary safety letter
Bridge Prep Kit: risk of delayed bleeding control
ANSM · R2630294; Merit K12-09098B/K12-09098C; Philips591-001. Notice / document or action commencement: 2026-11-16 / October 2026.
Merit Medical describes resistance that can prevent a Philips Bridge occlusion balloon from advancing over the InQwire Amplatz IQA502P guidewire supplied in Bridge Prep Kit. In an emergency, delay in controlling bleeding could cause serious harm or death. The manufacturer reports withdrawal of unexpired kits for the listed models. The letter provides interim precautions, including checking advancement of the paired devices before the procedure.
Official communication · Primary safety letter
Arrow PICC: New Zealand guidewire recall
Medsafe · Medsafe37934. Notice / document or action commencement: first verified 2026-11-16 / 2026-11-11.
Medsafe reports a New Zealand recall of affected Arrow PICC and Arrowg+ard Blue Advance PICC kits containing Spring Wire Guides. Hydration with saline can cause uneven swelling and detachment of the coating, creating an embolic risk when particles enter the bloodstream. Affected products should be returned under Teleflex’s instructions. This is a local action first verified in this run for a risk previously reported in other jurisdictions; it is not presented as a new global signal.
QPPV, LQPPV and LCPPV professionals may use the cited notices to assess relevance to their products and territories. Role names and responsibilities vary across jurisdictions.